Navigation Links
Anesiva Announces First Quarter 2008 Financial Results

SOUTH SAN FRANCISCO, Calif., May 8 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today reported financial results and accomplishments for the first quarter ended March 31, 2008 and provided an update on its commercialization activities for FDA-approved Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, as well as clinical development milestones for Adlea(TM), the company's long-acting, localized, non-opioid analgesic drug candidate.

"This is an exciting year for Anesiva as we prepare for the commercial introduction of our first product, Zingo, in the pediatric hospital setting, while pursuing a broader label to include adults," said John P. McLaughlin, chief executive officer of Anesiva. Zingo addresses the need for rapid (one to three minutes), topical local analgesia prior to peripheral IV starts and blood draws, and is approved for use in children three to 18 years of age.

There are approximately 18 million peripheral venous access procedures in children in U.S. hospitals each year. Most currently available products are impractical to use because of their long onset of action. Yet, approximately 74% of the time children must be restrained prior to venous access procedures because of the pain associated with these procedures, a fearful experience. Anesiva believes Zingo will offer healthcare providers an important alternative to address this unmet medical need.

"We've also advanced our clinical development program for Adlea in the management of acute pain following orthopedic surgery, having initiated two Phase 3 trials since the beginning of 2008," Mr. McLaughlin said. "Top-line data from both trials are anticipated by year-end."

The most common complaint among orthopedic surgery patients is pain following the procedure even when treated with opioids. In fact, the second and third most common complaints are the nausea and vomiting caused by the very opioids taken to manage pain. Adlea addresses the need for improved post-surgical pain management by providing a locally administered alternative without the side effects of systemic opioids and other standard pain medications. There are approximately 4.5 million orthopedic surgeries and arthroscopic procedures each year in the U.S., according to the American Academy of Orthopedic Surgeons.

Recent Highlights and Accomplishments

Anesiva continued its commercialization efforts for the second quarter launch of Zingo and to advance Adlea in Phase 3 trials:


-- In preparation for the Zingo U.S. launch in June 2008, Anesiva's

hospital-based sales force expanded its efforts to educate nurses and

physicians on the importance of treating the pain associated with IV

starts and blood draws and on the features and use of Zingo for their

pediatric patients. The Anesiva sales force is working with the sales

force of co-promotion and distribution partner Sagent Pharmaceuticals,

Inc., whose efforts are targeted at the hospital pharmacists critical

to gaining inclusion on drug formularies.

-- To grow the potential Zingo market, in March Anesiva submitted a

supplemental New Drug Application (sNDA) with the U.S. Food and Drug

Administration (FDA) to expand the indication for Zingo to include the

treatment of pain associated with peripheral IV insertions and blood

draws in adults. In U.S. hospitals, there are approximately 245 million

adult peripheral venous access procedures performed annually.

-- In line with the company's goal of establishing Zingo as a global

brand, Anesiva expanded the exclusive licensing and distribution

agreement signed earlier this year with Sigma-Tau; the agreement now

covers all major European markets except the British Isles and the

countries of Scandinavia. Discussions are underway to license Zingo in

those and in other major markets. Anesiva also signed an exclusive

marketing and distribution agreements with Green Vision Company for

major markets in the Middle East.

-- Publications in peer-reviewed journals on Zingo clinical trials, and

critical findings presented at medical meetings from market research

associated with the importance of treating IV pain, continue to

reinforce the need for a fast onset-of-action topical local anesthetic.

A recent survey of more than 2,000 pediatric nurses showed that nearly

all agree that inserting an IV line into a fearful, anxious child can

be challenging -- a situation that is encountered 76% of the time. The

nurses indicated that, although topical local anesthetics (TLAs) would

be beneficial in this setting, they are used less than a third of the

time. Barriers to use include slow onset of action (20 minutes or more)

and treatment delays, among others. Nearly all survey participants

(92%) agreed that patients would benefit from the use of a fast-acting

TLA for peripheral venous access procedures. The results of the survey,

which was sponsored by Anesiva, will be presented tomorrow at the

annual meeting of the American Pain Society.


-- The Phase 3 clinical development program was initiated with two pivotal

trials evaluating Adlea in patients undergoing total knee replacement

surgery and in patients undergoing bunionectomy surgery. These two

pivotal trials, along with supporting Phase 2 trials in other surgical

settings, are intended to support a broad product label for Adlea for

the management of acute post-operative pain following orthopedic

surgery. There were approximately 565,000 total knee replacement

procedures performed in the U.S. in 2005, and the number of

replacements is expected to grow as the average age of the population

increases and as people maintain active lives. The American Academy of

Orthopedic Surgeons projects that approximately 3.5 million of these

procedures will be performed annually by 2030.

First Quarter 2008 Financial Results and 2008 Outlook

Total operating expenses in the first quarter of 2008 were $21.8 million, including $1.6 million of non-cash stock-based compensation, compared to total operating expenses of $12.7 million, including $2.0 million of non-cash stock-based compensation, in the first quarter of 2007.

Operating expenses during the quarter primarily related to the continued development and commercial preparations to launch the company's lead product candidate, Zingo, a fast-acting, needle-free, local anesthetic. Additional operating expenses related to the ongoing development of Adlea, which has been shown in clinical studies to provide site-specific, moderate-to-severe pain relief for weeks to months following a single application.

For the first quarter of 2008, the net loss was $21.6 million, or $0.54 per share. In the first quarter of 2007, the net loss was $11.7 million, or $0.43 per share. Common shares outstanding were 40.4 million at March 31, 2008.

As of March 31, 2008, cash, cash equivalents and short-term investments were $70.0 million compared to $90.8 million at December 31, 2007. The company believes it has sufficient resources to fund anticipated expenses for the remainder of 2008 and into 2009.

Conference Call Details

Anesiva will conduct a webcast conference call with the investment community at 4:30 p.m. EDT, today, May 8, 2008 to discuss its financial results and to review the company's progress and future outlook. Interested parties can listen to the live conference call by dialing 866-616-3642 (international dial: 706-643-3817) or by logging on to and going to the Investor Information page. For those unable to participate via the Internet, a replay will be available for seven days after the call by dialing 800-642-1687 (international dial: 706-645-9291) and giving the following pass code: 45132379. The webcast will be available until the company's next quarterly financial results conference call.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. In clinical trials, the most common adverse reactions to Zingo were redness (erythema), red dots (petechiae) and swelling (edema). The second product in Anesiva's pipeline, Adlea(TM), reduces pain after only a single administration for weeks to months based on mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the timing and results of our clinical trials, including the results of the trials for Adlea, whether Anesiva is able to manufacture its products on commercially reasonable terms, whether Anesiva can secure FDA approval for the use of Zingo in adults, and the degree to which Zingo gains market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva's annual report on Form 10-K for the year ended December 31, 2007.

Anesiva undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

Anesiva, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

Three months ended

March 31,

2008 2007

(unaudited) (unaudited)

Contract revenue $1 $-

Operating expenses:

Research and development 13,384 6,962

General and administrative 8,457 5,754

Total operating expenses 21,841 12,716

Loss from operations (21,840) (12,716)

Interest and other income 248 1,038

Loss before minority interest (21,592) (11,678)

Minority interest in loss of variable

interest entity 9 -

Net Loss (21,583) (11,678)

Basic and diluted net loss per common share $(0.54) $(0.43)

Shares used to compute basic and diluted

net loss per common share 40,269 27,315

Stock-based compensation $1,562 $2,047

Anesiva, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

March 31, December 31,

2008 2007

(unaudited) (Note)


Cash, cash equivalents and short-term

investments $70,043 $90,840

Other current assets 3,193 2,225

Total current assets 73,236 93,065

Property and equipment, net 15,602 15,276

Other assets, non-current 1,381 1,395

Total assets $90,219 $109,736

Liabilities and stockholders' equity

Current liabilities $12,930 $12,175

Long term obligations 8,052 9,047

Minority interest 537 -

Total stockholders' equity 68,700 88,514

Total liabilities and stockholders' equity $90,219 $109,736

(Note): Derived from audited financial statements at that date.

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the ... million people each year. Especially those living in larger cities are affected by air ... one of the most pollution-affected countries globally - decided to take action. , “I ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today ... designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) ... able to cross the cell membrane and bind intracellular STAT3 and inhibit its ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder ... local San Diego Rotary Club. The event entitled “Stem Cells and ... had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
Breaking Biology News(10 mins):